{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T00:22:53Z","timestamp":1787962973778,"version":"build-2784847793"},"reference-count":8,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2025,5,23]],"date-time":"2025-05-23T00:00:00Z","timestamp":1747958400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,8,18]]},"abstract":"<jats:p>This letter highlights the successful use of obinutuzumab as an alternative therapy for a patient with pemphigus vulgaris who could not tolerate rituximab. Our findings suggest that obinutuzumab may offer a promising treatment option for patients with autoimmune skin diseases when first-line therapies fail.<\/jats:p>","DOI":"10.1093\/bjd\/ljaf201","type":"journal-article","created":{"date-parts":[[2025,5,23]],"date-time":"2025-05-23T05:37:01Z","timestamp":1747978621000},"page":"578-580","source":"Crossref","is-referenced-by-count":2,"title":["Successful treatment of pemphigus vulgaris with obinutuzumab"],"prefix":"10.1093","volume":"193","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-9307-5168","authenticated-orcid":false,"given":"Colin","family":"Tang-Whitmore","sequence":"first","affiliation":[{"name":"Department of Dermatology, University of Minnesota Medical School , Minneapolis, MN ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren","family":"Ostlund","sequence":"additional","affiliation":[{"name":"Department of Dermatology, MHealth Fairview , Minneapolis, MN ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kati","family":"Munson","sequence":"additional","affiliation":[{"name":"Department of Dermatology, MHealth Fairview , Minneapolis, MN ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brittney","family":"Schultz","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University of Minnesota Medical School , Minneapolis, MN ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,5,23]]},"reference":[{"key":"2025081809373609400_ljaf201-B1","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1016\/j.jdcr.2020.05.034","article-title":"Refractory pemphigus vulgaris successfully treated with ofatumumab","volume":"6","author":"Klufas","year":"2020","journal-title":"JAAD Case Rep"},{"key":"2025081809373609400_ljaf201-B2","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1111\/1346-8138.17108","article-title":"Ofatumumab subcutaneous injection successfully treated patients with pemphigus vulgaris relapse post rituximab","volume":"51","author":"Zhang","year":"2024","journal-title":"J Dermatol"},{"key":"2025081809373609400_ljaf201-B3","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.jdcr.2022.07.011","article-title":"Obinutuzumab in a patient with chronic lymphocytic leukemia-associated paraneoplastic pemphigus","volume":"27","author":"Freund","year":"2022","journal-title":"JAAD Case Rep"},{"key":"2025081809373609400_ljaf201-B4","doi-asserted-by":"crossref","first-page":"256","DOI":"10.4161\/mabs.2.3.11641","article-title":"The immunogenicity of humanized and fully human antibodies","volume":"2","author":"Harding","year":"2010","journal-title":"mAbs"},{"key":"2025081809373609400_ljaf201-B5","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1111\/bjh.15232","article-title":"A tale of two antibodies: obinutuzumab versus rituximab","volume":"182","author":"Freeman","year":"2018","journal-title":"Br J Haematol"},{"key":"2025081809373609400_ljaf201-B6","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1136\/annrheumdis-2021-220920","article-title":"B-cell depletion with obinutuzumab for the treatment of proliferative lupus nephritis: a randomised, double-blind, placebo-controlled trial","volume":"81","author":"Furie","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"2025081809373609400_ljaf201-B7","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.3389\/fimmu.2017.01245","article-title":"Therapeutic antibodies: what have we learnt from targeting CD20 and where are we going?","volume":"8","author":"Marshall","year":"2017","journal-title":"Front Immunol"},{"key":"2025081809373609400_ljaf201-B8","doi-asserted-by":"crossref","first-page":"572863","DOI":"10.3389\/fphar.2020.572863","article-title":"Rituximab hypersensitivity: from clinical presentation to management","volume":"11","author":"Fouda","year":"2020","journal-title":"Front Pharmacol"}],"container-title":["British Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/bjd\/advance-article-pdf\/doi\/10.1093\/bjd\/ljaf201\/63306498\/ljaf201.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/bjd\/article-pdf\/193\/3\/578\/63306498\/ljaf201.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/bjd\/article-pdf\/193\/3\/578\/63306498\/ljaf201.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,18]],"date-time":"2025-08-18T13:37:45Z","timestamp":1755524265000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/bjd\/article\/193\/3\/578\/8142198"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,23]]},"references-count":8,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2025,5,23]]},"published-print":{"date-parts":[[2025,8,18]]}},"URL":"https:\/\/doi.org\/10.1093\/bjd\/ljaf201","relation":{},"ISSN":["0007-0963","1365-2133"],"issn-type":[{"value":"0007-0963","type":"print"},{"value":"1365-2133","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,9]]},"published":{"date-parts":[[2025,5,23]]}}}